Sjögren's syndrome specific antibody

Diseases can often bring great disasters to the body, causing various adverse changes in the body, and ultimately affecting life safety and quality of life. For example, Sjögren's syndrome is a common disease that is very destructive and can cause serious damage to the body. Some people's bodies contain Sjögren's syndrome-specific antibodies, which can prevent the occurrence of the disease. Let's take a look at what Sjögren's syndrome-specific antibodies are.

Sjögren's syndrome (SS) is a chronic inflammatory autoimmune disease that mainly affects the exocrine glands, also known as autoimmune exocrine gland epithelial cell inflammation or autoimmune exocrinopathy. Clinically, in addition to dry mouth and dry eyes caused by damaged salivary glands and lacrimal glands, other exocrine glands and extra-glandular organs are affected, resulting in symptoms of multi-system damage. There are multiple autoantibodies and hyperimmunoglobulinemia in their serum. This disease is divided into two categories: primary and secondary.

Primary Sjögren's syndrome is a global disease with a prevalence of 0.3% to 0.7% in the Chinese population and 3% to 4% in the elderly population. This disease is more common in women, with a male to female ratio of 1:9 to 20. The age of onset is mostly between 40 and 50 years old. Also seen in children.

Among patients with Sjögren's syndrome, anti-SS-A and anti-SS-B antibodies can be found in the serum of most patients. These two antibodies are also found in many connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, etc., but the positive rate is not as high as that of Sjögren's syndrome. When these two antibodies are present, the possibility of Sjögren's syndrome should be considered first.

Anti-SS-B antibodies have high specificity but low sensitivity. Patients with anti-SS-B antibodies often also have anti-SS-A antibodies. Neither was associated with disease activity. In addition, these two antibodies are more likely to appear in patients with visceral damage.

Patients with concurrent neurological diseases, glomerulonephritis, interstitial lung disease, liver damage, low blood cells (especially low platelets), myositis, etc. should be given adrenal cortical hormones in the same dosage as for the treatment of other connective tissue diseases. For patients with rapidly progressive disease, immunosuppressants such as cyclophosphamide and azathioprine can be used in combination. Patients with malignant lymphoma should undergo active and timely combined chemotherapy.